Owlstone Medical said today it is launching a 1,400-patient clinical trial of its breath-based colorectal cancer diagnostic technology. The Intercept trial aims to explore the accuracy of the U.K.-based company’s ‘breathalyzer’ test in detecting colorectal cancer at an early stage. Owlstone’s breathalyzer uses field asymmetric ion mobility spectrometry to detect volatile organic compound metabolites in […]
Owlstone Medical
Owlstone Medical raises $11.6m for disease breathalyzer device
Owlstone Medical said today that it raised $11.6 million to help fund its disease breathalyzer device. The round was led by existing investors and follows an original investment of $7 million that spun the Cambridge, England-based company out in June last year. The funds will be used to commercially launch Owlstone’s breath biomaker R&D services, […]